Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 1172

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 7A
Chunk 1172
---
 segment are the same as those described in the “Summary of Significant Accounting Policies”
for the Company. All costs, research and development expenses, general and administrative expenses, other operating expenses, interest
expense, depreciation, corporate overhead assets (workforce, intellectual property, etc.) are fully allocated to the Company’s
one segment. Significant segment expenses include payroll and costs incurred for the Company’s primary third-party contract research
organization (“CRO”). During the years ended December 31, 2024 and 2023, the Company incurred payroll expenses classified
in our consolidated statements of operations as research and development of $1.0
million and $1.3
million,
respectively. During the years ended December 31, 2024 and 2023, the Company incurred payroll expenses classified in our consolidated
statements of operations as general and administrative of $0.5
million
and $0.4
million.
During the years ended December 31, 2024 and 2023, the Company incurred third-party CRO expenses of $2.1
million
and $0.1
million,
respectively, all of which is classified in our consolidated statements of operations as research and development. All other operating
expenses in our consolidated statements of operations are characterized as other segment expenses which, after factoring in other income
and expenses, reconcile to net loss for each period. The Company’s reportable segment’s profit or loss, assets, significant
expenses and other specified items are consistent with the financial information disclosed in our consolidated financial statements.
See the consolidated financial statements for the financial information of the Company’s one segment.

    F-26

Note
10 – Net Loss Per Share

The
calculation of basic and diluted earnings per common share is as follows (in thousands, except per share amounts):

 Schedule
of Earnings Per Share Basic and Diluted

    Numerator: 

    Net Loss, basic 
    $(9,144,797)
  
    Less: Change in fair value of warrant liabilities(1) 
     (395,078)
  
    Net Loss, diluted 
    $(9,539,875)

    Denominator: 

    Weighted average common stock outstanding, basic 
     2,870,120 
  
    Effect of dilutive securities: 

    Warrants 
     17,148 
  
    Weighed average common stock outstanding, diluted 
     2,887,268 
  
    Net loss per share